Device Survival Probability
SECURA_VR_SURV
| 1 yr | 2 yr | 3 yr | 4 yr | 5 yr | 6 yr | 7 yr | 8 yr | 9 yr | 10 yr | 11 yr | 12 yr | 13 yr | 14 yr | at 172.0 mo | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % |  |
100.0 | 99.9 | 99.9 | 99.9 | 99.8 | 99.8 | 99.7 | 99.6 | 99.6 | 99.6 | 99.6 | 99.6 | 99.6 | 99.6 | 99.6 | ||||||
| % |  |
99.8 | 99.6 | 99.3 | 99.0 | 98.6 | 98.0 | 96.2 | 91.1 | 77.0 | 54.6 | 46.6 | 44.8 | 43.8 | 43.5 | 43.3 | ||||||
| # | 17637 | 16328 | 15175 | 14070 | 12958 | 11844 | 10615 | 8585 | 5566 | 2897 | 2072 | 1578 | 1144 | 425 | 150 |
- Including Normal Battery Depletion – This curve includes devices that have reached at least 80% of expected longevity. This curve is most representative of clinical performance and how long the device will last.
- Excluding Normal Battery Depletion – This is the malfunction free survival curve.
Customer Communications For This Model
- There are no communications for this model.
Product Characteristics
| Generator Type | ICD |
|---|---|
| NBD Code | VVE-VVIR |
| Max. Delivered Energy | 35 J |
| Connector Style | Cx Style |
|---|---|
| Serial Number Prefix | PZF |
| Mass | 68 g |
| Volume | 37 cc |
| Waveform | Biphasic |
| X-Ray ID | PUG |
Estimated Longevity
| Charging Frequency | 100% Pacing | 50% Pacing | 15% Pacing | 100% Sensing |
|---|---|---|---|---|
| Monthly | 4.3 | 4.7 | 4.9 | 5.0 |
| Quarterly | 6.7 | 7.5 | 8.1 | 8.4 |
| Semi-annual | 7.8 | 8.9 | 9.8 | 10.3 |
Longevity estimates based on the following device usage. Pacing Mode VVI; Ventricular Lower Pacing Rate 60ppm; Ventricular Pulse Width 0.4ms; Ventricular Pulse Amplitude 3V; Ventricle Impedance 510ohms; Ventricle Sensing Rate 70bpm; EGM prestorage OFF; Optivol ON; Charging frequency assumes maximum energy charge and includes therapy shocks and capacitor formation. Hide this content
Distribution Data
| US Market Release | |
|---|---|
| CE Approval Date | 2008-03-14 |
| Registered USA Implants | |
| Estimated Active USA Implants | |
| Normal Battery Depletions |
| US Market Release | |
|---|---|
| CE Approval Date | 2008-03-14 |
| Estimated WW Distribution | 12761 |
| Normal Battery Depletions | 23 |
Malfunctions (USA)
| Therapy Function Not Compromised | |
|---|---|
| Therapy Function Compromised |
Malfunctions (WW)
| Therapy Function Not Compromised | 33 |
|---|---|
| Battery | 8 |
| Electrical Component | 17 |
| Possible Early Battery Depletion | 3 |
| Software/Firmware | 5 |
| Therapy Function Compromised | 11 |
| Battery | 5 |
| Electrical Component | 6 |
EOS Indication
The Prolonged Service Period (PSP) is the time between the RRT and EOS. The PSP is defined as 3 months assuming the following conditions: 100% VVI pacing at 60 min-1, 2.5 V RV pacing amplitude; 0.4 ms pulse width; 600 Ω pacing load; and 6 full-energy charges. The EOS may be indicated before the end of 3 months if the device exceeds these conditions.
Recommended Replacement (RRT)
Battery voltage less than or equal to 2.63V on 3 consecutive daily automatic measurements.
Charge Time
D204VRM_D214VRM_D224VRC_D234VRC_CHRG
Data as of November 20, 2024